Nymox Nears Completion of Latest U.S. Study of NX-1207 for Benign Prostatic Hyperplasia
HASBROUCK HEIGHTS, NJ (April 15, 2008) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company’s latest multi-center U.S. Phase 2 study of its proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia (BPH) is nearing completion. The Company anticipates the reporting of final results and statistical analysis for the study within the next few weeks.
The results of the blinded clinical trials to date have shown
that men treated with NX-1207 reported statistically significant
improvement in BPH symptoms 3 months after a single NX-1207
treatment. In two multi-center Phase 2 U.S. prospective
randomized blinded clinical trials, the aggregated mean improvement
in the Primary Endpoint of BPH Symptom Score for 2.5 mg NX-1207 was
10.3 points or a 44% improvement in Symptom Score. To date,
subjects treated with NX-1207 have reported no serious side effects
from the treatment, including no (0%) significant sexual side
effects.
Results of 5 follow-up studies of available subjects from NX-1207
clinical trials have provided evidence of durable benefits from
NX-1207 treatment for up to 3 ½ years from the date of
treatment.
NX-1207 treatment is administered by intraprostatic injection of a
single dose by a urologist in an office setting. The entire
procedure lasts on average 5-10 minutes, with the injection taking
1-2 minutes, and does not require anesthesia or
catheterization.
BPH treatment represents a growing market with more than 100
million men worldwide being estimated to suffer from BPH symptoms.
The disorder is a common affliction of older men, affecting
approximately half of men over age 50 and close to 90% of men by
age 80, and is associated with growth in prostate size as men age.
BPH causes difficulties with urination associated with aging, such
as urination at night, urge to void frequently, hesitancy, weak
stream, and other problems, and can cause acute urinary retention
requiring immediate medical attention.
More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.
This press release contains certain “forward-looking
statements” as defined in the United States Private
Securities Litigation Reform Act of 1995 that involve a number of
risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and the actual results and
future events could differ materially from management's current
expectations. The conduct of clinical trials and the development of
drug products involve substantial risks and uncertainties and
actual results may differ materially from expectations. Promising
early results do not ensure that later stage or larger scale
clinical trials will be successful or will proceed as expected.
Such factors are detailed from time to time in Nymox's filings with
the United States Securities and Exchange Commission and other
regulatory authorities.
For Further Information Contact:
Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Posted: April 2008
